Last updated: 6 days ago
AstraZeneca's Form 6-K: Breakthrough Datroway Results in Metastatic TNBC Treatment
AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.